December 17, 2015—Medicaid would have received an additional $1.4 billion in rebates on the top 200 generic drugs for 2005 through 2014 if the rebate calculation for generic drugs contained an inflationary adjustment similar to the one applicable to brand-name drugs, the Department of Health and Human Services Office of Inspector General says in a new report.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)